These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 22045098

  • 1. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
    Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, Chan HW, Li CS, Wong SS, Ho YW, Cheuk A, Tong MK, Tang SC.
    Perit Dial Int; 2012; 32(3):280-91. PubMed ID: 22045098
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K, Douma CE, Ferrantelli E, Ter Wee PM, Beelen RHJ, van Ittersum FJ.
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [Abstract] [Full Text] [Related]

  • 5. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ.
    Cochrane Database Syst Rev; 2014 Mar 27; (3):CD007554. PubMed ID: 24671928
    [Abstract] [Full Text] [Related]

  • 6. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
    Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Ahn C, Kim MJ, Shin SK.
    Perit Dial Int; 2005 Mar 27; 25(3):248-55. PubMed ID: 15981773
    [Abstract] [Full Text] [Related]

  • 7. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
    Tomo T.
    Perit Dial Int; 2008 Jun 27; 28 Suppl 3():S123-7. PubMed ID: 18552241
    [Abstract] [Full Text] [Related]

  • 8. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
    Yung S, Lui SL, Ng CK, Yim A, Ma MK, Lo KY, Chow CC, Chu KH, Chak WL, Lam MF, Yung CY, Yip TP, Wong S, Tang CS, Ng FS, Chan TM.
    Perit Dial Int; 2015 Jun 27; 35(2):147-58. PubMed ID: 25904773
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
    Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, Kim CD, Park SH, Yoon KW.
    Perit Dial Int; 2008 Jun 27; 28 Suppl 3():S101-6. PubMed ID: 18552237
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.
    le Poole CY, Welten AG, ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, Beelen RH, van den Born J, van Ittersum FJ.
    Perit Dial Int; 2012 Jun 27; 32(3):305-15. PubMed ID: 22045100
    [Abstract] [Full Text] [Related]

  • 13. A new neutral-pH low-GDP peritoneal dialysis fluid.
    Himmele R, Jensen L, Fenn D, Ho CH, Sawin DA, Diaz-Buxo JA.
    Perit Dial Int; 2012 Jun 27; 32(4):444-52. PubMed ID: 22383632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
    Park SH, Lee EG, Kim IS, Kim YJ, Cho DK, Kim YL.
    Perit Dial Int; 2004 Jun 27; 24(2):115-22. PubMed ID: 15119632
    [Abstract] [Full Text] [Related]

  • 16. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
    Nau B, Schmitt CP, Almeida M, Arbeiter K, Ardissino G, Bonzel KE, Edefonti A, Fischbach M, Haluany K, Misselwitz J, Kemper MJ, Rönnholm K, Wygoda S, Schaefer F, European Pediatric Peritoneal Dialysis Study Group.
    BMC Nephrol; 2004 Oct 14; 5():14. PubMed ID: 15485574
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effects of peritoneal dialysis solutions on peritoneal host defense.
    Mortier S, Lameire NH, De Vriese AS.
    Perit Dial Int; 2004 Oct 14; 24(2):123-38. PubMed ID: 15119633
    [Abstract] [Full Text] [Related]

  • 19. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, Law MC, Li PK.
    Nephrol Dial Transplant; 2007 Feb 14; 22(2):552-9. PubMed ID: 17005526
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
    Johnson DW, Clarke M, Wilson V, Woods F, Brown FG.
    BMC Nephrol; 2010 Sep 16; 11():25. PubMed ID: 20843375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.